Prenatal Exposure to Carbamazepine Reduces Hippocampal and Cortical Neuronal Cell Population in New-Born and Young Mice without Detectable Effects on Learning And Memory

Elin Åberg1,*, Sarah Holst2, Alexandru Neagu1, Sven Ove Ögren2, Catharina Lavebratt1

1 Neurogenetics Unit, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden, 2 Department of Neuroscience, Karolinska Institute, Stockholm, Sweden

Abstract

Pregnant women with epilepsy have to balance maternal and fetal risks associated with uncontrolled seizures against the potential teratogenic effects from antiepileptic drugs (AEDs). Carbamazepine (CBZ) is among the four most commonly used AEDs for treatment of pregnant epileptic women. We previously reported that new-born children had a decreased head circumference after in utero CBZ exposure. This study investigates how prenatal exposure of CBZ influences the number of neurons in new-born and young mouse hippocampus, amygdala and cortex cerebri. Clinical studies describe inconclusive results on if prenatal CBZ treatment influences cognition. Here we investigate this issue in mice using two well characterized cognitive tasks, the passive avoidance test and the Morris water maze test. Prenatal exposure of CBZ reduced the number of neurons (NeuN-immunoreactive cells) in the new-born mouse hippocampus with 50% compared to non-exposed mice. A reduction of neurons (20%) in hippocampus was still observed when the animals were 5 weeks old. These mice also displayed a 25% reduction of neurons in cortex cerebri. Prenatal CBZ treatment did not significantly impair learning and memory measured in the passive avoidance test and in the Morris water maze. However, these mice displayed a higher degree of thigmotaxic behaviour than the control mice. The body weight of prenatally CBZ exposed five-week old mice were lower compared to control mice not exposed to CBZ (p = 0.001). In conclusion, prenatal exposure to CBZ reduces the number of neurons dramatically in areas important for cognition such as hippocampus and cortex, without severe impairments on learning and memory. These results are in line with some clinical studies, reporting that CBZ has minor negative effects on cognition. The challenge for future studies are to segment out what possible effects a reduction of neurons could have on different types of cognition, like intellectual ability and social interaction.

Introduction

Epilepsy affects 1–2% of humans worldwide and one third of those are women in reproductive age [1,2]. Both seizures and antiepileptic drug (AED) treatment during pregnancy are thought to influence the child negatively. The risk of major fetal congenital malformations as a cause of the disease is approximately 1–2% [3,4] but this risk is even 2–3 fold higher in women with epilepsy treated with AEDs [5,6,7,8]. Thus, pregnant women with epilepsy have to balance maternal and fetal risks associated with uncontrolled seizures against the potential teratogenic effects from AEDs. The most commonly used AEDs for treatment of pregnant epileptic women today are valproate (VPA), phenytoin (PHT), carbamazepine (CBZ) and lamotrigine (LTG) [9].

AEDs are not only subscribed to individuals with epilepsy, but are also used as mood stabilizers in psychiatric disorders [10]. In addition, pregnancy increases the risk for the onset and recurrence of several psychiatric disorders and pregnant women suffering from affective disorders do often require treatment with mood stabilizers (lithium carbonate, VPA, CBZ, LTG), antidepressants and/or antipsychotics [11,12].

Congenital heart disease, cleft lip and/or palate, limb defects, genitourinary malformations and neural tube defects are malformations seen after AED treatment [13,14,15,16]. Also cognitive impairments, intellectual disability and maladaptive behaviors are associated with exposure to AEDs in utero [9,17,18,19,20,21]. It is widely accepted that VPA is associated with more side effects compared to the other commonly used AEDs and that polytherapy regimes are more harmful than monotherapy regimes [9,17,18,19,21,22,23,24,25,26,27,28,29]. Long-term effects into adulthood induced by in utero exposure of AEDs have not been extensively studied, even though there are some follow up studies indicating that almost all AEDs have negative effects on later
intellectual functioning [20,30,31,32,33]. Moreover, the mechanisms behind cognitive impairments caused by AEDs are still not well described although a few animal studies have given some clues [34,35,36].

We made a retrospective study on all Swedish singleton births between 1995 and 2005 (over 900,000 births) obtained from the Swedish medical birth registry, and demonstrated a reduced head circumference at birth in newborns exposed to CBZ in utero [37]. Previous studies of cognitive performances in young children (up till 6 years of age) exposed to CBZ in utero demonstrate conflicting results. Some investigations demonstrate general developmental delay, impaired language and IQ scores [38,39,40,41], while other studies could not detect any cognitive difference in performances between CBZ exposed children and controls [20,29,42,43].

The present study was conducted to investigate whether in utero exposure to CBZ can affect the neuronal hippocampal cell population in newborn mice. In addition, we examined the effect of prenatal CBZ exposure on neuronal cell populations in hippocampus, cortex cerebri and amygdala in five-week old mice and related these changes to cognitive performances. Cognitive performance was evaluated by use of the Passive Avoidance (PA) test and the Morris water maze test, which are well characterised cognitive tasks of emotional [44,45] respective spatial learning and memory. Two different mouse strains (BALB/c mice and C57BL/6 mice) were used in this study. They were housed, 2–7/cage (offspring) or 1–2/cage (pregnant dams), in standard transparent M3 Makrolon® cages lined with bedding material (Scabant's Aspen wood Bedding, Scabant, Sweden) in a light/temperature/humidity-controlled environment: 12-h light/dark cycle (light on at 06:00 h), temperature 22°C and 40–50% humidity. Tap water and food pellet (R34 pellet or CBZ diet, Lantmannen, Sweden) was provided ad libitum.

**Materials and Methods**

**Ethics Statement**

All animals were handled according to guidelines approved by a local ethics committee (Stockholm Northern Ethics Board of Animal Experimentation) in Sweden.

**Animals**

Male and female mice, BALB/c and C57BL/6 (Scanbur, Sweden; Taconics, Germany) were used to produce offspring examined in this study. They were housed, 2–7/cage (offspring) or 2–3/cage (pregnant dams), in standard transparent M3 Makrolon® cages lined with bedding material (Scabant's Aspen wood Bedding, Scabant, Sweden) in a light/temperature/humidity-controlled environment: 12-h light/dark cycle (light on at 06:00 h), temperature 22°C and 40–50% humidity. Tap water and food pellet (R34 pellet or CBZ diet, Lantmannen, Sweden) was provided ad libitum.

**Exposure to CBZ.** Starting one week before a male mouse was placed in the cage, the female mice were given CBZ diet (3.5 g CBZ/kg in normal R34 pellet, Lantmannen, Sweden) up to the time of delivery. CBZ diet was replaced with normal R34 pellets, without CBZ, directly after delivery. This CBZ diet has been shown to result in serum levels of CBZ in mice well above the minimal effective dose in humans, but below the optimal therapeutic range for human antiepileptic therapy [46]. The control female mice received normal R34 pellet, (Lantmaunen, Sweden) during the same time period. The body weight of the newborn pups was not recorded to avoid disturbing the dam and her pups. For the same reasons the pregnant dams were not monitored for signs of toxicity. However, the numbers of litters and the number of survived pups were noted when the mice were three weeks old. The body weight was measured at five weeks of age.

Female and male BALB/c offspring were used to investigate the effect of prenatal CBZ exposure on the hippocampal and cortical neuronal cell counts in newborn (n = 15) and in young (five weeks old, n = 15) mice. Another group of 5 weeks old male and female BALB/c mice was used to investigate the effect of prenatal CBZ exposure on the cognitive abilities in the PA test (n = 19). Two separate groups of female and male C57BL/6 offspring were used to investigate the effect of prenatal CBZ exposure on spatial learning and memory in the Morris water maze test (age: five weeks (n = 11) and nine weeks (n = 10)). The C57BL/6 mice were used, since BALB/c mice were poor performers in this test.

**Perfusion**

Newborn pups were decapitated and the brains dissected and incubated in fixative solution (4% paraformaldehyde and 0.4% picric acid in 0.16 M PBS, pH 7.4) for 2 h at room temperature (RT). The brains were then rinsed and stored in sucrose (10% in PBS, 0.1% sodium azide) at 4°C and thereafter snap-frozen in dry-ice-cooled iso-pentane.

5 weeks old mice were deeply anesthetised by pentobarbital and then perfused intracardially at forced pressure with 10 ml Ca2+-free Tyrode’s solution including 0.1 ml heparin, followed by 50 ml of the fixative solution. The brains were dissected and postfixed in the same fixative for 1 h at RT, rinsed and stored in the sucrose solution at 4°C, and thereafter snap-frozen.

**Immunohistochemistry**

The brains were cryosectioned in 30 μm coronal sections encompassing the entire hippocampus in a cryostat and mounted on Super-Frost slides. Mouse on mouse (M.O.M) kit for immunodetection (Vector, Burlingame, CA) was used for NeuN staining according to the manufacturer's protocol. The sections were incubated with the primary antibody (anti-NeuN, 1:100, Chemicon) for 24 h at 4°C and with biotinylated secondary antibody (anti-mouse IgG, 1:250, M.O.M kit) for 1 h in RT. To enhance signals, ABC Vectastain Elite Reagent (Vector) was applied for 40 min at RT. After detection with 3’3’-diaminobenzidine substrate (DAB, Sigma) for 30 seconds in RT the slides were dehydrated and mounted with Pertex (Histolab, Gothenburg Sweden).

**Stereology**

The “Optical fractionator” [47,48] was used to estimate the number of neurons in the dentate gyrus (DG), in the CA1 and CA3 regions of the hippocampus, in cortex cerebri and in amygdala of CBZ exposed and control mice. In newborn mice, neuronal cell counts were determined in the rostral part of hippocampus (~3.5 mm from Bregma to ~4.5 mm from Bregma) [49] combining the hippocampal regions CA1 and CA3. Cell counts in five weeks old mice were determined through the entire hippocampus (~0.9 mm from Bregma to ~3.9 mm from Bregma) [50]. Here, neurons in DG were counted as one entity whereas neuron counts from the CA1 and CA3 regions were combined. Neuronal cell counts in cortex cerebri and amygdala (~1.6 mm from Bregma to ~2.1 mm from Bregma) were also counted [50].

Every tenth section was systematically sampled after that the first section within the first interval had been chosen randomly. An unbiased counting frame of known area was superimposed on the field of view by stereological analysis software (Stereologer™, SPA inc., VA, USA). These counting frames were then automatically and systematically distributed throughout the marked region originating from a random starting point. The optical fractionator estimates are unbiased, since no assumptions are made about cellular shape and size, and not affected by tissue shrinkage during
tissue processing. Before counting an area of interest, the areas were manually outlined using a 10 x lens; whereas a 60 x lens with a numerical aperture of 1.4 was used for cell counts. Only cells that fell within the frame or bordered the inclusion lines were counted, while cells touching exclusion lines were omitted. These steps were performed with a light microscope (Olympus BH-2) modified for stereology with the following components: a computer-driven motorized Marzhaüser stage (Marzhaüser Wetzlar GmbH & Co. KG, Wetzlar-Steindorf, Germany), a microscope (Heidenhain, Traunreut, Germany) and a CCD camera. All stereological analyses were conducted in one hemisphere of the brain.

Passive Avoidance

The PA task is an associative learning paradigm based on contextual fear conditioning (Pavlovian conditioning), involving neuronal circuits in the limbic forebrain, such as hippocampus and amygdala [44,51]. In the step-through PA procedure, performed in a two-compartment box, the suppression of the innate preference of rodents for the dark compartment following the exposure to an inescapable foot shock is defined as PA behavior [44,45,52,53]. Memory retention was tested in a computer-controlled PA (TSE-Systems GmbH, Homburg, Germany).

The experiments were performed between 8 a.m. and 3 p.m. Test of memory retention was performed 24 hours after the training [52,53]. During training the mouse was placed in a bright compartment (BC, 330 lux) (280 x 155 x 160 mm) for 60 s. Then the door between the compartments opens and the mouse has free access to the dark compartment (DC) (280 x 155 x 160 mm). Upon entering the DC the door closes after 3 s and the mouse received weak electrical current (US) (duration 1 s) 0.30 mA. The mouse was left in the dark compartment for 60 s after the aversive cue (US) had been presented to increase the association of the context (C) and placed in the bright compartment (BC, 330 lux) (280 x 155 x 160 mm). Upon leaving the BC the mouse was placed in the dark compartment (DC) (280 x 155 x 160 mm). Memory retention was examined by measuring the latency time to the first transfer from the BC to the DC with a cut-off latency of 10 min (600 s [45,52,53]). After the end of each test, the arena was cleaned and deodorised after each animal using 70% ethanol.

Morris Water Maze

The water maze (180 cm in diameter; 45 cm in height) was filled to a depth of 28 cm with tap water (23°C) and placed in the center of a room surrounded by several cues. All studies were performed under dim light conditions (Ogren et al., 1996). Pretreatment was performed during three days followed by training during six days, both with four 90 s long trials/day. A 60 s long retention test was performed twenty-four hours after the last training session.

During pre-training the platform (10 cm in diameter) was located 1 cm below the water surface, but was made visible for the animals. The platform location was changed every trial and the periphery of the water tank was covered by a curtain to prevent access to extra-maze cues. During training the platform was located 1 cm below the water surface and invisible to the animal. The platform location remained constant over the six days of training, but was removed at retention on day seven. Before starting the experiments the mice were allowed to habituate to the water maze room for one hour. The water maze system (Water Maze Software, Edinburgh, UK) allow measurements of latency to find the platform, swim distance, swim speed, thigmotaxic behavior as well as quadrant and zone analyses (Cain et al., 1996; Steele and Morris, 1999; Luttgert et al., 2005). A circular area (radius 20 cm from the center of the platform) was defined as the target zone, equivalent to 4.9% of the total water maze area. Thigmotaxic swimming, was defined as the percentage of total time the mice spent swimming within 10 cm from the walls of the water maze.

Statistical analysis

The results are presented as means ± SEM. The data were analyzed for normality. Normally distributed data were analyzed with parametric tests. Differences between groups were tested with one way-analysis of variance (ANOVA) in the PA task. Student’s t test was applied to analyse cell counting data from both new-born and five-week old animals.

The behavioural data were first visually assessed for normality by the sample distribution. Normally distributed results were analysed with parametric test. Differences between the groups were tested with one way- analysis of variance (ANOVA). Significant differences between groups were tested with the Fisher LSD test. The nonparametric test Kruskall Wallis was used for data that were not normally distributed. P<0.05 was regarded as statistically significant. All data were analyzed with the computer software program Statistica® 7.0.

Results

Prenatal exposure of carbamazepine reduced the number of hippocampal pyramidal neurons in newborn BALB/c mice with 50%

Prenatal CBZ exposure reduced the number of mature neurons (NeuN-immunoreactive cells) in the CA1 and CA3 regions of hippocampus (P = 0.0013, Fig. 1A) by 50% compared to the control group not exposed to CBZ. There were no mature neurons in the dentate gyrus in the newborn mice (Fig. 1B).

Prenatal CBZ exposure had long-term effects on hippocampal and cortical pyramidal cells in young BALB/c mice

Prenatal CBZ exposure reduced the number of mature neurons in hippocampal CA1 and CA3 regions in 5 week-old mice, compared to non-exposed mice (P = 0.0004, Fig. 2A). CBZ exposure had no effect on neurons in the dentate gyrus (data not shown).

Stereological counting of NeuN-positive neurons in cortex cerebri revealed that the number of mature neurons was lower in mice that had been exposed to CBZ in utero than in non-exposed mice, (P = 0.0008, Fig. 3A). However, CBZ did not affect neurons in amygdala.

Prenatal CBZ exposure had no effect on learning and memory in young mice

The step-through latency retention in the passive avoidance test was similar between CBZ-exposed and non-exposed BALB/c mice demonstrating that prenatal treatment with CBZ had no effect on amygdala hippocampal-dependent emotional type of learning and memory (Fig. 4). Likewise, the results from the Morris water maze test showed that prenatal CBZ exposure had no effect on hippocampal-dependent spatial learning and memory (Fig. 5). However, the CBZ exposed C57BL/6 mice displayed an anxious and thigmotaxic behaviour demonstrated by that they spent more time closely to the walls of the pool compared to the non-exposed mice (P = 0.0092, Fig. 5D, H).
Prenatal treatment with CBZ decreased the number of litters, weaned pups and body weight.

The number of litters/dam was reduced two times as a result of CBZ exposure during pregnancy. Non-exposed dams had 4 litters/dam during the breeding period while the CBZ exposed dams only had 2 litters/dam. The average number of weaned pups/dam and litter was lower in the group prenatally exposed to CBZ (2.8 pups/dam and litter) compared to non-exposed dams (7.5 pups/dam and litter). In addition, five weeks old mice prenatally exposed to CBZ had a significantly lower body weight than non-exposed mice ($P = 0.001$, Table 1).

**Discussion**

This is the first study, to our knowledge, investigating the effects of prenatal exposure of CBZ on hippocampal, amygdala and cortical neurons, which are indeed important areas for learning and memory. The major findings in this study are that prenatal exposure of CBZ reduces the number of neurons in the new-born mouse hippocampus, indicated by a 50% reduction of NeuN-immunoreactive cells and that prenatal exposure to CBZ also affects the cell population in five-week old mouse hippocampus and cortex cerebri. Thus, the neurodegenerative effects from prenatal CBZ exposure is long-lasting and are not restricted to hippocampus but also found in cortex cerebri. Interestingly, reduction of neurons were found in hippocampal CA1 and CA3 and cortex cerebri pyramidal cells but not in granule cells in the dentate gyrus and medium spiny neurons in the amygdala. Some cell types may be more sensitive to teratogens than others, in agreement with for example Charriaut-Marlangue et al., Crepel et al and Pellegrini-Giampietro et al. [54,55,56]. Since granule cells primarily develop during the early postnatal period, which is after CBZ exposure, their development may have been unaffected [57,58]. In addition, Cochrane (2009) suggests that AED exposure in utero can achieve a precise type of cognitive disturbance by generating a more specific or strong effect in certain brain areas compared to others [9].

Based on the inconclusive results in clinical studies of the effect of prenatal CBZ exposure on cognition [17,20,21,29,39,40,41,42,43] we examined the effect of prenatal CBZ exposure on learning and memory in young (5 week-old) BALB/c mice using the Passive Avoidance (PA) test which involves neuronal circuits in the limbic forebrain, such as hippocampus and amygdala. Our intention was, in addition to the PA test, to also...
investigate BALB/c mice in the Morris water maze task, which is mainly a hippocampus-dependent spatial learning and memory task [59,60]. However, the BALB/c mice displayed an abnormally high amount of thigmotaxic behaviour, in which they swam around the walls of the pool almost continuously, without any attempt to reach the platform and to get out of the pool. The behaviour could be viewed as a displacement behaviour, displayed in place of other behaviours, when neither being in the water nor out in the open was enough rewarding to perform. The desire to avoid the open of the pool mirrors a higher level of emotionality in this mouse strain. The BALB/c is considered to be a more anxious mouse strain than the C57BL/6 [61,62]. Since the escape latency in BALB/c could be due to both anxiety and cognition we evaluated the effect of prenatal CBZ exposure on spatial cognition using the C57BL/6 in the Morris water maze. Prenatal CBZ treatment had no detectable effects on learning and memory, neither in the PA nor in the Morris water maze test. These results are in line with most of the clinical investigations performed, which demonstrate that CBZ has minor effects on cognition, especially compared to VPA [17,20,42,43].

Prenatally CBZ treated C57BL/6 mice also displayed the anxiety-like behaviour, thigmotaxis, in the Morris water maze. Whether this is due to a direct CBZ toxic effect on the neural circuits involved in regulating anxiety or an overall effect of CBZ on homeostasis is unknown. It could also be due to fewer cage mates (or occasionally none) for the CBZ exposed animals. The decreased body weight found in the prenatally treated mice could be associated with the increased anxiety level in these animals. Decreased body weight and increased level of anxiety could also separately be a result of CBZ toxicity mentioned in the below section. Whether CBZ has a general toxic effect on the brain neuronal network, or if it hits specific networks, is a question for further investigations.

Pregnant dams treated with CBZ got two times fewer litters/dam compared to non-exposed dams. The average number of weaned pups/dam and litter was also lower in the group prenatally exposed to CBZ compared to non-exposed dams recorded at an age of 3 weeks. In addition, prenatal CBZ exposure also decreased the body weight recorded at five-weeks of age. The decreased number of weaned pups prenatally exposed to CBZ could be due to impaired mating, impaired survival of embryos, absorption of foetuses, less nutrition during the gestation period, complicated parturition, impaired maternal care as well as impaired feeding behaviour or success in competition for food. The role of CBZ in different stages of development as well as on the maternal behaviour and pup response needs to be further elucidated.

CBZ has been demonstrated to induce mitotic arrest in human kidney-derived cell lines [63]. Postnatal CBZ administration to rats on day 7/day 8 did not result in detectable effects on cell proliferation, neurogenesis or cell death [35,36]. The effects of CBZ exposure may be different depending on if the exposure is
CBZ reduces brain neuronal cell population postnatal or prenatal. The reduction of neurons found in this investigation could possibly be caused by a decrease in cell proliferation, altered neurogenesis or neurodegeneration. AEDs can down-regulate neurotrophic factors, such as BDNF and NT-3 [34]. It is thus possible that CBZ down-regulated the trophic support for neurons and that this in turn caused neuronal death. AEDs have also been demonstrated to alter intracellular pathways involved in survival promoting signalling. Further studies are needed to address possible mechanisms behind the decrease of the neuronal cell population found after prenatal CBZ exposure.

This is the first study to investigate prenatal CBZ treatment and the effects on brain neuronal cell populations in combination with learning and memory. However, there are some limitations in this study. 1. As already mentioned, BALB/c could be used only in one of the learning and memory tests performed. However, similar to the lack of detectable effect of prenatal CBZ exposure on emotional learning in BALB/c, there was no effect on spatial learning in the C57BL/6 mice. 2. Toxicity of CBZ in pregnant mice or CBZ effects on new-borns, were not investigated in this study. Body weight was only recorded in five-week old mice. The CBZ dose used has been shown to result in serum levels of CBZ well above the minimal effective dose in humans, but below the optimal therapeutic range for human antiepileptic therapy [46]. 3. CBZ-exposed mice were fewer than those not exposed to CBZ in the passive-avoidance test. Still, adequate statistical models and analyses were performed.

The last Cochrane review (2009) stated the necessity to generate data establishing the effects of in utero AED exposure on child development and cognition [9]. When translating the findings of our study to humans the differences in brain developmental stages between rodents and humans should be considered, where the human brain goes through more stages in utero than the rodent brain does [64,65] and also the longer drug-exposure time in utero for human fetuses compared to rodent fetuses.

In conclusion, the present study demonstrates that in utero exposure to CBZ produces a drastic reduction of mature hippocampal and cortical neurons. Interestingly, no apparent cognitive impairment was detected in the PA test or in the Morris water maze despite this huge reduction of neuron count. This proposes that the loss of neurons in brain areas important for cognition possibly can be compensated for by long-term structural rearrangements of neuronal networks. However, another interpretation may be that CBZ does not affect emotional memory and spatial learning, but rather influence other aspects of cognition like intellectual ability and social interaction. Further studies are

Table 1. Prenatal exposure to carbamazepine (CBZ) influences mouse body weight. Exposed mice had a lower body weight than non-exposed mice.

|                         | BALB/c [5 weeks] |
|-------------------------|------------------|
| CBZ-exposed mice        | 14.7 ± 0.48 (6)*** |
| Non-exposed mice        | 17.7 ± 0.30 (13)  |

The weight is presented in grams and as mean ± SEM (n).

***P < 0.001 compared to non-exposed mice.

doi:10.1371/journal.pone.0080497.t001
required to scrutinize the influence of the CBZ-Caused loss of neurons on cognitive functions.

Author Contributions
Conceived and designed the experiments: EA SH SOO CL. Performed the experiments: EA SH. Analyzed the data: EA SH AN. Contributed reagents/materials/analysis tools: EA SOO CL. Wrote the paper: EA.

References
1. Hauser WA (1994) The prevalence and incidence of convulsive disorders in children. Epilepsia 35 Suppl 2: 81–6.
2. Wallace H, Shoreen S, Tallin R (1998) Age-specific incidence and prevalence rates of untreated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 352: 1970–1973.
3. Crawford P, Appleton R, Bets T, Duncan J, Guthrie E, et al. (1999) Best practice guidelines for the management of women with epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure: the journal of the British Epilepsy Association 8: 201–217.
4. Olafsson E, Hallgrimsson JT, Hauser WA, Ludvigsson P, Gudmundsson G (1998) Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 39: 887–892.
5. Holmes LB, Harvey EA, Cowill BA, Huntington KB, Khoshbin S, et al. (2001) The teratogenicity of anticonvulsant drugs. The New England journal of medicine 344: 1132–1138.
6. Samren EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, et al. (1997) Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38: 981–990.
7. Samren EB, van Duijn CM, Christiansen GC, Hofman A, Lindhout D (1999) Antiepileptic drug regimens and major congenital abnormalities in the offspring. Annals of neurology 46: 739–746.
8. Kanae S, Battino D, Andermann E, Wada K, Kan R, et al. (1999) Congenital malformations due to antiepileptic drugs. Epilepsy research 33: 145–158.
9. Adab N, Toshur SC, Vinten J, Williamson P, Winterbottom J (2004) Common antiepileptic drug-induced in pregnancy in women with epilepsy. Cochrane database of systematic reviews: CD004848.
10. Galbally M, Roberts M, Buist A (2010) Mood stabilizers for mood disorders in pregnancy. Current opinion in psychiatry 24: 34–40.
11. Gentile S (2011) Drug treatment for mood disorders in pregnancy. Current opinion in psychiatry 24: 34–40.
12. Gentile S (2010) Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depression and anxiety 27: 675–678.
13. Kaplan PW, Norway ER, Ben-Menachem E, Pennell PB, Druzin M, et al. (2007) Obstetric risks for women with epilepsy during pregnancy. Epilepsy & behavior: E&B 11: 283–291.
14. Meador KJ, Pennell PB, Hardin CL, Gordon JC, Tomson T, et al. (2000) Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology 71: 1109–1117.
15. Pennell PB (2004) Pregnancy in women who have epilepsy. Neurologic clinics 22: 799–820.
16. Morrow JI, Hunt SJ, Russell AJ, Smithson WH, Parsons L, et al. (2009) Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of neurology, neurosurgery, and psychiatry 80: 506–511.
17. Meador KJ, Baker G, Cohen MJ, Gaily E, Westervelt M (2007) Cognitive/behavioral teratogenic effects of antiepileptic drugs. Epilepsy & behavior: E&B 11: 292–302.
18. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Canter D, et al. (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England journal of medicine 360: 1509–1516.
19. Bromley RL, Baker GA, Browning N, Clayton-Smith J, Combs-Canter D, et al. (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England journal of medicine 360: 1509–1516.
20. Adab N, Kini U, Vinten J, Ayres J, Baker G, et al. (2004) The longer term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug safety: an international journal of medical toxicology and drug experience 33: 73–79.
21. Vinten J, Bromley RL, Taylor J, Adab N, Kini U, et al. (2009) The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy & behavior: E&B 14: 197–201.
22. Vinter J, Adab N, Kini U, Gorry J, Grege J, et al. (2005) Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 64: 949–954.
23. Eriksson K, Viimikainen K, Monkkonen A, Alkia M, Nieminen P, et al. (2005) Children exposed to valproate in utero–population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy research 63: 189–200.
24. Thomas SV, Ayakumar B, Sindhu K, Nair MK, George B, et al. (2008) Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy & behavior: E&B 13: 229–236.
25. Adab N, Jacobs A, Smith D, Chadbick D (2001) Additional educational needs in children born to mothers with epilepsy. Journal of neurology, neurosurgery, and psychiatry 70: 15–21.
26. Tine K, Koch S, Helge H, Lehmkuhl U, Rauh H, et al. (2000) Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Developmental medicine and child neurology 50: 117–122.
27. Desens A, Cohen-Kettenis P, Mellenbergh G, van de Poll N, Koppje J, et al. (1999) Prenatal exposure to anticonvulsant drugs and spatial ability in adulthood. Acta neurobiologiae experimentalis 59: 221–225.
28. Sulzbacher S, Farswll JR, Temkin N, Lu AS, Hirtz DG (1999) Late cognitive effects of early treatment with phenobarbital. Clinical pediatrics 38: 387–394.
29. Reinch J, Sanders SA, Mortensen EL, Rubin DB (1995) In utero exposure to phenobarbital and intellectual functioning in adults. JAMA: the journal of the American Medical Association 274: 1518–1523.
30. Bitigau P, Sifring J, Mrsz G, Reith E, Pospschall D, et al. (2002) Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proceedings of the National Academy of Sciences of the United States of America 99: 15089–15094.
31. Chen J, Cai F, Cao J, Zhang X, Li S (2009) Long-term antiepileptic drug administration during early life inhibits hippocampal neurogenesis in the developing brain. Journal of Neuroscience research 87: 2899–3007.
32. Kim J, Kondratyev A, Gale K (2007) Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. The Journal of pharmacology and experimental therapeutics 325: 163–173.
33. Almgren M, Kallen B, Lavebratt C (2009) Population-based study of antiepileptic drug exposure in utero–influence on head circumference in newborns. Seizure: the journal of the British Epilepsy Association 18: 672–675.
34. Jones KL, Lacrov RC, Johnson KA, Adams J (1989) Pattern of malformations in the children of women treated with carbamazepine during pregnancy. The New England journal of medicine 320: 1661–1666.
35. Ornoy A, Cohen E (1996) Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Archives of disease in childhood 75: 517–520.
36. Dran JC, Hailly H, Moore SJ, Lloyd DJ, Tampenny PD, et al. (2002) Long-term health and neurodevelopment in children exposed to antiepileptic drugs before birth. Journal of medical genetics 39: 251–259.
37. Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J (2011) Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Archives of disease in childhood 96: 643–647.
38. Gaily E, Kantola-Sorsa E, Hulnesmaa V, Isahao M, Matila R, et al. (2004) Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 62: 20–32.
39. Scoulak D, Nulman I, Rovet J, Gladstone D, Czuchta D, et al. (1994) Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA: the journal of the American Medical Association 271: 767–770.
40. Baarendse PJ, van Grootheest G, Jansen RF, Pieneman AW, Ogren SO, et al. (2008) Differential involvement of the dorsal hippocampus in passive avoidance learning. The Journal of neuroscience: the official journal of the Society for Neuroscience 28: 4515–4527.
41. Lavebratt C, Trifunovski A, Persson AS, Wang FH, Klaos T, et al. (2006) Carbamazepine protects against megnephalia and abnormal expression of BDNF and Nogo signaling components in the mceph/mceph mouse. Neurobiology of disease 24: 374–383.
42. West MJ, Gunderson HJ (1990) Unbiased stereological estimation of the number of neurons in the human hippocampus. The Journal of comparative neurology 296: 1–22.
48. West MJ, Słomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. The Anatomical record 231: 482–497.

49. Paxinos G, Halliday G, Watson C, Koutcherov Y, Wang H (2007) Atlas of the Developing mouse brain. Academic Press, Elsevier.

50. Franklin K, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic Press.

51. LeDoux JE (1995) Emotional memory systems in the brain. Behavioural brain research 38: 69–79.

52. Madjid N, Tottie EE, Lutgen M, Meister B, Sandin J, et al. (2006) 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. The Journal of pharmacology and experimental therapeutics 316: 581–591.

53. Eriksson TM, Madjid N, Elvander-Tottie E, Stiedl O, Svenningson P, et al. (2008) Blockade of 5-HT 1B receptors facilitates contextual aversive learning in mice by disinhibition of cholinergic and glutamatergic neurotransmission. Neuropsychopharmacology 34: 1041–1050.

54. Pellegrini-Giampietro DE, Gorter JA, Bennett MV, Zukin RS (1997) The GluR2 (GluR-B) hypothesis: Ca(2+) permeable AMPA receptors in neurological disorders. Trends in neurosciences 20: 464–470.

55. Charriaut-Marlangue C, Aggoun-Zouaoui D, Represa A, Ben-Ari Y (1996) Apoptotic features of selective neuronal death in ischemia, epilepsy and gp 120 toxicity. Trends in neurosciences 19: 109–114.

56. Crepel V, Epststein J, Ben-Ari Y (2003) Ischemia induces short- and long-term remodeling of synaptic activity in the hippocampus. Journal of cellular and molecular medicine 7: 401–407.

57. Bayer SA, Altman J (1974) Hippocampal development in the rat: cytogenesis and morphogenesis examined by autoradiography and low-level X-irradiation. The Journal of comparative neurology 158: 55–79.

58. Dobbing J, Sands J (1979) Comparative aspects of the brain growth spurt. Early human development 3: 79–83.

59. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. Journal of neuroscience methods 11: 47–60.

60. D’Hooge R, De Deyn PP (2001) Applications of the Morris water maze in the study of learning and memory. Brain research Brain research reviews 36: 60–90.

61. Lepicard EM, Joubert C, Hagneau I, Perez-Diaz F, Chapoussiere G (2000) Differences in anxiety-related behavior and response to diazepam in BALB/cByJ and C57BL/6J strains of mice. Pharmacology, biochemistry, and behavior 67: 739–748.

62. Old F, Sillaber I, Binder E, Keck ME, Heideber F (2001) Differential analysis of behavior and diazepam-induced alterations in C57BL/6N and BALB/c mice using the modified hole board test. Journal of psychiatric research 35: 147–154.

63. Perez Martin JM, Fernandez Freire P, Labrador V, Hazen MJ (2008) Carbamazepine induces mitotic arrest in mammalian Vero cells. Mutation research 657: 124–133.

64. Quinn R (2003) Comparing rat’s to human’s age: how old is my rat in people years? Nutrition 21: 775–777.

65. Dwyer JB, McQuown SC, Leslie FM (2009) The dynamic effects of nicotine on the developing brain. Pharmacology & therapeutics 122: 125–139.